Alpha-lipoate can protect against glycation of serum albumin, but not low density lipoprotein

Biochem Biophys Res Commun. 1994 Aug 30;203(1):99-104. doi: 10.1006/bbrc.1994.2154.

Abstract

Protein glycation may play a role in the pathogenesis of diabetic complications. alpha-Lipoate (1,2-dithiolane-3-pentanoate) has been reported to prevent glycation and structural modification of bovine serum albumin (BSA). To elucidate the protective mechanism, we tested the effects of enantiomerism, thiol moiety and hydrophobicity of alpha-lipoate on glycation of BSA and low density lipoprotein (LDL). When BSA (1 mM) was incubated with 500 mM glucose in the presence of alpha-lipoate homologues or dihydrolipoate (6,8-dimercaptooctanoate, DHLA) at 37 degrees C for 72 h, both alpha-lipoate (racemic, R- and S-forms) and DHLA inhibited BSA glycation similarly, but tetranorlipoate (1,2-dithiolane-3-carboxylate) did not. However, under similar conditions, alpha-lipoate did not inhibit LDL glycation. Scatchard plot analysis demonstrated that 6 mol of alpha-lipoate bind to 1 mol of BSA with a formation constant of 8.7 x 10(4) M-1. Therefore, we concluded that alpha-lipoate protects BSA glycation by hydrophobic binding near the glycation sites of BSA.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Glycated Serum Albumin
  • Glycation End Products, Advanced
  • Glycosylation
  • Humans
  • Isomerism
  • Lipoproteins, LDL / drug effects
  • Lipoproteins, LDL / metabolism*
  • Protein Binding
  • Serum Albumin / metabolism*
  • Serum Albumin, Bovine / drug effects
  • Serum Albumin, Bovine / metabolism*
  • Structure-Activity Relationship
  • Thioctic Acid / pharmacology*

Substances

  • Glycation End Products, Advanced
  • Lipoproteins, LDL
  • Serum Albumin
  • glycated lipoproteins, LDL
  • Serum Albumin, Bovine
  • Thioctic Acid
  • Glycated Serum Albumin